Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
In the PLATO substudy referring to patients presenting with an ST-elevation Myocardial
Infarction(STEMI), out of the 4201 who received ticagrelor, 1326 had been pre-treated with a
600mg clopidogrel loading dose (LD) within 24 hours prior to randomization. It is a logical
assumption, that patients who are being reloaded with ticagrelor will demonstrate reduced
platelet reactivity (PR) at 24 hours, in comparison to those who were initially loaded with
ticagrelor, due to the synergistic antiplatelet effect. Single loading with ticagrelor
though, will possibly be accompanied by a smaller bleeding potency compared to reloading with
ticagrelor. Therefore, we assume that single loading with ticagrelor is non-inferior to
reloading with ticagrelor, in terms of platelet reactivity.
P2Y12 inhibitor naive patients with STEMI, they will be randomized immediately after coronary
angiography (Hour 0) in receiving either Ticagrelor 180mg LD or Clopidogrel 600mg LD and 2
hours later reloading with Ticagrelor 180mg, after written informed consent. PR will be
measured, using the VerifyNow assay at randomization (Hour 0) and at 2, 4, 6 and 24 hours
post randomization. In addition, a 12-lead ECG will be performed before randomization, 90 and
180 minutes after the first balloon inflation, as well as on the exit day. Troponin I and
CK-MB will be assessed at randomization and at hour 4, 12, 24, 48 and 72 after randomization.
Non inferiority of Ticagrelor LD versus Ticagrelor re-LD would be accepted if the upper bound
of the 2-sided 95% CI around the estimated LS mean difference (Ticagrelor LD minus Ticagrelor
re-LD) in the primary end point (PR at 24 hours) would lie bellow Δ=35 PRU. This
non-inferiority margin (Δ) represents the upper bound of the LS mean difference in PR between
Ticagrelor and Prasugrel arm at 24 hours after LD in a pharmacodynamic study of 55 STEMI
patients.
Considering previous studies PR at 24 hours post randomization was estimated at 47±40 PRU and
41±35 PRU for Ticagrelor only LD and Ticagrelor re-LD group respectively. To obtain 85%
statistical power with a 2-sided alpha=0.05, approximately 32 patients in each treatment
group (64 in total) would be needed to establish the primary hypothesis using the
abovementioned non-inferiority margin of 35 PRU. Anticipating a 5% dropout rate, enrollment
was set to at least 68 patients. The primary endpoint, as well as PR at all the other time
points of the study will be analyzed separately via a mixed effect model with treatment as
fixed effect, patient as a random intercept and PR at baseline as a covariate. Least squares
estimates of the mean difference will be presented, with 95% confidence intervals and a
two-sided p-value for the treatment effect. P values for secondary endpoints will be reported
for two-tailed tests of superiority.